title: Test-firing ammunition for spliceosome inhibition in cancer.
abstract: E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy. Clin Cancer Res; 19(22); 6064-6. ©2013 AACR.
authors.affiliation: Author's Affiliation: Masonic Cancer Center and Department of Laboratory Medicine and Pathology, University of Minnesota, Twin Cities.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Dehm
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004852:Epoxy Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D017381:Spliceosomes / Q000187:drug effects*
chemical_list: D000903:Antibiotics, Antineoplastic; C557411:E 7107; D004852:Epoxy Compounds; D018942:Macrolides